Transdermal Versus Oral Oxybutynin in Pediatric OAB

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

July 15, 2019

Study Completion Date

May 1, 2020

Conditions
Overactive Bladder (OAB)Drug Delivery SystemsAnticholinergic Side EffectsChildren and Adolescents, Boys and Girls
Interventions
DRUG

Oral Oxybutynin

The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.

DRUG

transdermal oxybutinin

The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.

Trial Locations (1)

34890

Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Dr. Lutfi Kirdar Kartal Training and Research Hospital

OTHER_GOV

NCT07081906 - Transdermal Versus Oral Oxybutynin in Pediatric OAB | Biotech Hunter | Biotech Hunter